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Table I. Sites of polymorphism in POMC cDNA
Human pituitary POMC cDNA AGCGCGCCTACGATCGTCGCAGCCCAGC
Human skin POMC cDNA (variant) CTTATCTGGGTTCCTACTATCCAGTGCT
Mouse POMC cDNA CTTATCTGGGTTCCTACTATCCAGTGCT
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Reply
This is in response to Ancans et al’s letter addressing the recently
published article by Can et al (1998) on the presence of a putative
POMC mRNA variant in human epidermis.
It is true that polymerase chain reaction (PCR) may introduce
errors resulting in amplification of a wrong sequence as suggested
by Ancans et al; however, based on our findings and for the reasons
detailed below, we are very confident that the sequence we have
reported is correct and is not due to an error in sequencing or
contaminated mouse sequence.
PCR experiments were performed using cultured normal human
melanocytes and keratinocytes (obtained from neonatal foreskins)
from well-established laboratories of my collaborators, Zalfa Abdel-
Malek and Steven Boyce at the University of Cincinnati.
The primers used in PCR were designed using human exon 2
and 3 sequences of POMC, and RNA from human cells were
used in PCR experiments. A human POMC plasmid (pH – 0X3)
obtained from Dr. James Roberts (Mount Sinai Medical Center,
NY) was also used.
Mouse anterior pituitary tumor cells (AtT20) was used as a
positive control only in in situ hybridization experiments. In PCR,
these cells were used only in the beginning to optimize the
conditions for PCR and were omitted during subsequent PCR
experiments, contrary to the comments presented by Ancans et al.
PCR experiments, cloning and sequencing of PCR products
were carried out at least three different times (n 5 3) from each
cell type obtained from different donors without the inclusion of
AtT20 cells. Thus there was no chance of contamination by
mouse cells.
In addition, recently we designed the sense primer TAC ATC
CGG GCC TGC AAG CCC CA and the anti-sense primer TCC
TAA CTA CAG GCA GCT TTA AGA CGC based on the human
exon 3 sequence (Takahashi et al, 1983). These primers were used
to clone most of exon 3 of human POMC gene from human
melanocytes, keratinocytes, and normal human skin. A PCR
product of µ676 bp was obtained in these cells and tissues and in
the AtT20 cell line. The comparison of the sequence of this PCR
product revealed 85%–89% homology with human POMC exon
3 and 100% homology with mouse POMC exon 3. The sequence
analysis was carried out at least three times (n 5 3) using different
donors for melanocytes and keratinocytes and without including
AtT20 cells. Also, I would like to point out that the sequencing
was performed at two different facilities (University of Cincinnati
DNA Core Facility and Marshall University, West Virginia DNA
Core Facility) with identical results.
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The experiments described above and the experiments that were
published in this journal were carried out over a 2 y time period
and were performed independently by different laboratory staff
who used different sources of reagents and different donors of
human melanocytes, keratinocytes, and normal human skin and
without the inclusion of AtT20 cells. Given these conditions it is
highly unlikely, if not impossible, that the same error or contamina-
tion would be duplicated.
To us the data suggest the presence of a variant form of POMC
mRNA in human epidermis and epidermal cells in culture. This
phenomenon has been well documented in various tissues by
different investigators. For example, as is well documented in our
paper, larger POMC mRNA transcripts have been reported in
murine and hamster melanoma cells (Slominski, 1991), trout
pituitary (Salbert et al, 1992), and nonpituitary ACTH-producing
tumors, thymic carcinoid, and pancreatic tumors (Eberle, 1988).
On the other hand, shorter POMC mRNA transcripts (µ200–
400 bp less) have been documented in normal adrenal glands,
ovary, testis and thymus in animals (Jeannotte et al, 1987), and in
human tissues (DeBold et al, 1988, Gallinelli et al, 1995). Recently,
we have reported the presence of a shorter or truncated form of
POMC mRNA (µ0.9 kb) in mouse Thy11 dentritic cells
(Farooqui et al, 1995). It has been postulated that these truncated
forms of POMC mRNA transcripts may arise as a consequence of
alternative splicing, variation in the length of the poly1 (A) tail,
or use of alternative transcription initiation site (Oates and Herbert,
1984; Lacaze-Masmonteil et al, 1987). Although the functional
significance of the variant POMC mRNA is not clear, it appears
to vary in a tissue-specific manner. It is our future goal to isolate
and identify the different POMC products that may be processed
by this variant POMC mRNA in human skin.
Without actually comparing our results and experimental condi-
tions with those of Ancans et al that have not been published yet,
it remains impossible for anyone to make any judgments about the
validity of the results.
Jamal Farooqui
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